About us
Protecting our tomorrow
A firm focus on vaccines stands at the core of everything we do.
READ MORE
Our strategy
Our Leadership Team
Executive Management
Board of Directors

Governance
Articles of Association
Board Practices
Policies
Remuneration Reports

Business Ethics
Code of Conduct
Ethics Hotline
Responsible Sourcing
Sustainability
Sustainability Reports
Recognitions
What we do
From R&D to manufacturing
We are focused on the research, development and manufacturing of innovative life-saving vaccines
READ MORE
Products

Pipeline
Chikungunya
Equine encephalitis
Immuno-oncology

Technology
INVESTORS
Investors
We are committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
News
Subscribe
Events & Presentations
Financials

Stock information
Stock Chart
Analysts
Ownership
ADR Program

Annual Report 2022
Annual General Meeting
Shareholder Portal
FAQ
IR Policy
Careers
Careers
We offer a challenging international working environment in which job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Our Culture
Diversity and Inclusion

Our Employees

Job Openings
Our Recruitment Process

News

Click here for news in Danish.

September 04, 2023 | Company Announcements

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

September 01, 2023 | Company Announcements

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

August 31, 2023 | Company Announcements

Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program

August 23, 2023 | Company Announcements

Bavarian Nordic Announces First Half 2023 Results

August 06, 2023 | Company Announcements

Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents

August 03, 2023 | Company Announcements

Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government

July 22, 2023 | Company Announcements

Bavarian Nordic Provides Update on RSV Vaccine Program

June 27, 2023 | Company Announcements

Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate

June 23, 2023 | Company Announcements

Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve

June 20, 2023 | Company Announcements

Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age

June 16, 2023 | Company Announcements

Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate

June 12, 2023 | Company Announcements

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

May 23, 2023 | Company Announcements

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

May 17, 2023 | Company Announcements

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program

May 15, 2023 | Company Announcements

Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions

May 09, 2023 | Company Announcements

Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations

May 09, 2023 | Company Announcements

Bavarian Nordic Announces Interim Results for the First Three Months of 2023

April 11, 2023 | Company Announcements

Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial

March 30, 2023 | Company Announcements

Resolutions of the Annual General Meeting 2023 of Bavarian Nordic A/S

March 16, 2023 | Company Announcements

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

March 07, 2023 | Company Announcements

Bavarian Nordic A/S – Notice Convening Annual General Meeting

March 02, 2023 | Company Announcements

Bavarian Nordic Publishes Annual Report 2022

February 23, 2023 | Company Announcements

Bavarian Nordic A/S - Registration of Share Capital Increase of 7,046,839 New Shares Completed

February 20, 2023 | Company Announcements

Bavarian Nordic A/S Announces Completion of Directed Issue of 7,046,839 New Ordinary Shares

February 20, 2023 | Company Announcements

Bavarian Nordic A/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue